Tenax Therapeutics, Inc.
TENX
$9.01
-$0.06-0.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 258.14% | 194.76% | 125.75% | 35.57% | 19.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 203.93% | 168.77% | 153.90% | 136.74% | 108.66% |
| Operating Income | -203.93% | -168.77% | -153.90% | -136.74% | -108.66% |
| Income Before Tax | -197.55% | -150.42% | -139.64% | -128.27% | -107.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -197.55% | -150.42% | -139.64% | -128.27% | -107.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -197.55% | -150.42% | -139.64% | -128.27% | -107.01% |
| EBIT | -203.93% | -168.77% | -153.90% | -136.74% | -108.66% |
| EBITDA | 53.04% | 8.59% | -47.05% | -136.88% | -108.62% |
| EPS Basic | 92.88% | 95.87% | 89.91% | 84.16% | 86.98% |
| Normalized Basic EPS | 92.88% | 95.87% | 89.91% | 84.15% | 86.99% |
| EPS Diluted | 92.88% | 95.87% | 89.91% | 84.16% | 86.98% |
| Normalized Diluted EPS | 92.88% | 95.87% | 89.91% | 84.15% | 86.99% |
| Average Basic Shares Outstanding | 513.68% | 3,413.47% | 4,439.52% | 5,924.11% | 3,337.59% |
| Average Diluted Shares Outstanding | 513.68% | 3,413.47% | 4,439.52% | 5,924.11% | 3,337.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |